Contrast-induced nephropathy (CIN) is a known complication of intravenous, iodinated contrast and is a common cause of acute kidney injury (AKI) in the inpatient setting. Th e reported incidence of CIN varies among studies, due to diff erences in defi nition, type and dose of contrast medium, study population, imaging procedure and the frequency of other potential causes of AKI [1] . Th e widely used defi nition for CIN is as an acute rise of 0.5 mg/dl in serum creatinine or a relative increase of more than 25% from the baseline value. CIN is usually transient, with serum creatinine beginning to rise within 24 to 48 hours after exposure, reaching a peak within 3 to 5 days after the administration of the contrast medium,
and returning to baseline within 7 to 10 days after administration [2] . Th e pathogenesis of CIN is not completely defi ned, and suggests a combination of toxic injury to the renal tubules and ischemic injury, partly mediated by reactive oxygen species [3] .
Th e CIN incidence can range from 2% to more than 40% in high-risk patients [4] [5] [6] [7] [8] [9] . Although the reported need for acute hemodialysis is low [1, 10] , patients develop ing CIN have longer hospital stays, more complicated clinical courses and higher mortality rates [1, 4] . Th e relationship of CIN to long-term adverse events is controversial. Only a small number of studies report kidney function beyond a few days after exposure to the contrast medium. In one study, the rate of long-term adverse events was higher in individuals with CIN after adjustment for baseline comorbidities and risk factors [11] . Although these data signal a worse long term in patients with contrast nephropathy, there is still insufficient evidence to reach a defi nitive conclusion.
Pre-existing chronic kidney disease is the greatest risk factor in the development of CIN. Other factors include diabetes, age over 75 years, heart failure, cirrhosis, hypertension, anemia, intra-arterial injection, hypotension, intra-aortic balloon pump and volume of contrast [12] . Most of these risk factors are often found in patients who have been admitted to the ICU. Additionally, computerized tomography with intravenous administration of iodinated radiographic contrast media is a frequent and necessary procedure for the management of critically ill patients in a variety of situations. However, the risk for CNI from radio-contrast exposure has not been well evaluated in this population.
In the previous issue of Critical Care, Cely and colleagues performed a single-center prospective matched cohort study of ICU patients requiring CT scanning with or without radio contrast to determine the incidence of CIN [13] . Th ey matched patients based on pre-scan measured creatinine clearance, diabetes and mechanical ventilation. Th e primary end point was a decrease in measured creatinine clearance by 33% within 3 days following scanning. Th e decline in renal function was equally frequent in groups scanned with and without Abstract Contrast-induced nephropathy is a common form of hospital-acquired acute kidney injury. Incidence is low in patients with normal renal function but increases in high-risk patients. Patients with contrast-induced nephropathy have higher in-hospital complication rates and mortality. Critically ill patients have been assumed to be a high-risk group for contrast-induced nephropathy. In the previous issue of Critical Care, Cely and colleagues showed an unexpectedly low incidence of contrast-induced nephropathy in critically ill patients receiving radiographic contrast material for computerized tomography. We should note that it is diffi cult to establish the true frequency and impact of the contrast nephrotoxicity because of many other causes for acute kidney injury in this population. Moreover, the impact on long-term kidney function and the possible eff ect of this insult on the recovery of renal function when associated with other causes of acute kidney injury are unknown. radiographic contrast material (RCM). Without a control group who were not exposed to contrast, the decreased glomerular fi ltration rate following the RCM was attributed to CIN. However, a similar rate of decline in renal function experienced by patients scanned without RCM leads to the conclusion that the loss of glomerular fi ltration rate in this scenario cannot be attributed solely to the RCM exposure.
A frequent decline in renal function and substantial daily variation in serum creatinine is known to occur in critically ill patients, whether or not they have been exposed to contrast-media injections [14] . Depending on the criteria in use, these fl uctuations in serum creatinine can determine diff erent incidences of CIN-associated AKI. Th e impact of the fl uctuations of renal function in critically ill patients on the diagnosis of CIN has also been discussed by Bruce and colleagues [15] . Considering these fi ndings and the results of the present study by Quartin and colleagues, it becomes clear that AKI after the administration of RCM may be refl ective of other processes occurring simultaneously in the critically ill patient. In this context, the diagnosis of CIN is challenging. Instead of ruling out CIN, other possible causes of AKI should be considered. Th erefore, patients suspected of CIN must also be evaluated for other possible causes of AKI [16] .
Before we accept a low incidence of CIN in critically ill patients, other important factors should be mentioned. Th e majority of patients in the study by Quartin and colleagues received CIN prophylaxis. Th e average fl uid administration exceeded 3 l on the day of scanning among both contrast patients and noncontrast patients. CIN is a preventable cause of AKI and, even if the incidence in ICU patients may be low, prophylaxis should always be carried out. Furthermore, CIN has unfavorable outcomes and the long-term outcomes in patients with CIN are uncertain. Whether CIN can increase the severity of AKI and the time to recover renal function is still un known.
Identifi cation of earlier and etiologic-specifi c biomarkers for CIN will probably allow determination of the real incidence of CIN and the development of targeted therapies. Currently, the use of delta creatinine in a 12-hour period after contrast exposure could be an alternative with good sensitivity and speci fi city for early detection [17] . While waiting for a more sensitive and specifi c biomarker for CIN, clinicians should weigh the benefi t of scanning with contrast media against the shortterm and long-term risks of CIN-associated AKI.
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